Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
Side-by-side · Research reference

PancragenvsSNAP-8

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/39 cited
BHuman-MechanisticHUMAN-REVIEWED8/46 cited
Pancragen
Bioregulatory Tetrapeptide · Khavinson School
50 μgPrimate doseGoncharova 2014
10 daysTreatment cycleGoncharova 2015
3+ weeksEffect persistenceGoncharova 2014
IM · 10-day cycleGoncharova 2014
SNAP-8
Synthetic Octapeptide · Cosmetic Topical
TopicalRoute
8-AAPeptide length
SNAREPrimary target
Topical · Facial application · Twice daily

01Mechanism of Action

Parameter
Pancragen
SNAP-8
Primary target
Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013
SNARE complex (SNAP-25 competitive binding site)
Pathway
Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013
Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation
Downstream effect
Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014
Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction
Feedback intact?
Yes — preserves physiological glucose-insulin response
N/A — topical cosmetic, no systemic endocrine axis
Origin
Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)
Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)
Antibody development

02Dosage Protocols

Parameter
Pancragen
SNAP-8
Primate dose (rhesus macaque)
50 μg / animal / dayGoncharova 2014
20–25-year-old females, 10-day IM protocol.
Effective concentration (in vitro)
0.05 ng/mLZakutskiĭ 2006
Organotypic tissue culture, both young and aged rat explants.
Route
IntramuscularGoncharova 2015
Frequency
Once daily for 10 daysGoncharova 2014
Treatment cycle
10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014
Evidence basis
Non-human primate RCT, in vitro cell cultureGoncharova 2015Khavinson 2013
RCT, in vitro skin penetration studies
Diabetes model
STZ-induced diabetes (rat)
Evaluated via metabolic markers characterizing apoptosis.
Typical concentration
2–10% in cosmetic formulationsLupin 2024Raikou 2017
Commercial products typically use 5–10%.
Application frequency
Twice daily (morning and evening)Lupin 2024
Treatment duration
20–60 days for visible effectRaikou 2017
Skin microtopography improvements measured at 20-day intervals.
Formulation type
Oil-in-water emulsion, serum, cream
Application site
Facial skin — glabellar lines, crow's feet, forehead
Onset of effect
Visible reduction in wrinkle depth by day 20–28Raikou 2017

03Metabolic / Fat Loss Evidence

04Side Effects & Safety

Parameter
Pancragen
SNAP-8
Reported adverse events
None documented in primate studies
Tolerability
Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015
Human safety data
No published human trials; clinical use limited to Russian gerontology protocols
Cytotoxicity
Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)
Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.
Skin irritation
Minimal; well-tolerated in clinical use
Peptide oxidation
Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021
Formulation stability issue, not a direct adverse effect.
Systemic absorption
Negligible; peptide remains in stratum corneum and epidermisKraeling 2015
Hypersensitivity
Rare; no widespread allergic reactions reported
Absolute Contraindications
Pancragen
SNAP-8
  • ·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients
Relative Contraindications
Pancragen
  • ·Active pancreatic malignancy (proliferation marker upregulation)
SNAP-8
  • ·Active skin infections or open wounds at application site
  • ·Neuromuscular disorders (theoretical concern, no documented cases)

05Administration Protocol

Parameter
Pancragen
SNAP-8
1. Reconstitution
Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.
Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.
2. Route
Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015
Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.
3. Timing
No specific timing constraints documented. Administered once daily in primate protocols.
Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.
4. Cycle structure
10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014
Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.
5. Storage
Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.
6. Duration
Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.